TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26637987

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccination at 6 months
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccination at 12 months
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccination at 15 months
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 183
Study: 24703415

Group type: EXPERIMENTAL
Intervention: Egg breakfast (EB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cereal breakfast (CB)
Number of subjects: 20
Study: 23063375

Group type: COMPARATOR
Intervention: Mirabegron 50 mg once daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mirabegron 100 mg once daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mirabegron 200 mg once daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mirabegron 300 mg once daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mirabegron (various doses)
Number of subjects: 120
Study: 19916246

Group type: EXPERIMENTAL
Intervention: SMOFlipid (soybean oil, medium‐chain triglycerides, olive and fish oil)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Lipid emulsion based on olive and soybean oil (Control)
Number of subjects: 44
Study: 17786128

Group type: EXPERIMENTAL
Intervention: Therapeutic Drug Monitoring (TDM)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: TDM-directed dose modifications
Number of subjects: 190
Study: 14681839

Group type: EXPERIMENTAL
Intervention: Copper supplementation (3 mg copper/d as copper-glycinate) for 6 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Copper supplementation (3 mg copper/d as copper-glycinate) plus zinc supplementation (30 mg zinc/d as zinc-glycinate) for 6 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 38
Study: 12077738

Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 50

Group type: COMPARATOR
Intervention: BHI 30(t=0)
Number of subjects: 50

Group type: COMPARATOR
Intervention: BHI 30(t=-30)
Number of subjects: 50
Study: 9449404

Group type: EXPERIMENTAL
Intervention: Potassium 40 mmol, Calcium 30 mmol (1200 mg), Magnesium 14 mmol (336 mg)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Calcium 30 mmol (1200 mg)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Magnesium 14 mmol (336 mg)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Potassium, Calcium, and Magnesium together
Number of subjects: 300
Study: 7616978

Group type: EXPERIMENTAL
Intervention: Morphine sulfate (1.9 mg/mL) plus droperidol (0.125 mg/mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Morphine sulfate (2 mg/mL)
Number of subjects: 40
Study: 2374275

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (1.5 g three times daily)
Number of subjects: 13
Study: 605762

Group type: EXPERIMENTAL
Intervention: 1.0 microgram/kg i.v. naloxone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2.5 microgram/kg i.v. naloxone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2.5 microgram/kg i.m. naloxone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 5.0 microgram/kg i.m. naloxone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no naloxone)
Number of subjects: 100
Study: 31409606

Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg once daily for 8 weeks
Number of subjects: 468

Group type: COMPARATOR
Intervention: lansoprazole 30 mg once daily for 8 weeks
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg once daily for 2 weeks
Number of subjects: 468

Group type: COMPARATOR
Intervention: lansoprazole 30 mg once daily for 2 weeks
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg once daily for 4 weeks
Number of subjects: 468

Group type: COMPARATOR
Intervention: lansoprazole 30 mg once daily for 4 weeks
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg once daily for 2 weeks (baseline LA grade C/D)
Number of subjects: 468

Group type: COMPARATOR
Intervention: lansoprazole 30 mg once daily for 2 weeks (baseline LA grade C/D)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg once daily for 4 weeks (baseline LA grade C/D)
Number of subjects: 468

Group type: COMPARATOR
Intervention: lansoprazole 30 mg once daily for 4 weeks (baseline LA grade C/D)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg once daily for 8 weeks (baseline LA grade C/D)
Number of subjects: 468

Group type: COMPARATOR
Intervention: lansoprazole 30 mg once daily for 8 weeks (baseline LA grade C/D)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: vonoprazan
Number of subjects: 468

Group type: COMPARATOR
Intervention: lansoprazole
Number of subjects: 468
Study: 30204841

Group type: EXPERIMENTAL
Intervention: Positively framed side effect information
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Negatively framed side effect information
Number of subjects: 112

Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 112
Study: 27838568

Group type: EXPERIMENTAL
Intervention: Medial Thrust
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Trunk Lean
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 30
Study: 24930996

Group type: EXPERIMENTAL
Intervention: Balance-based torso-weighting (BBTW)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matched velocities for healthy controls
Number of subjects: 20
Study: 23890785

Group type: EXPERIMENTAL
Intervention: Bard-Parker #15 scalpel blade
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Monopolar electrocautery (blend function, 1; power, 20 Watts; frequency, 480 kHz)
Number of subjects: 21
Study: 21429025

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) - i.v. infusion of 3.0 µg/kg per h over 5 min followed by continuous infusion at 0.4 µg/kg per h (n = 30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Propofol (PF) (n = 30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Midazolam (MDZ) (n = 30)
Number of subjects: 90
Study: 19961636

Group type: EXPERIMENTAL
Intervention: PSV plus ATC (ATC group)
Number of subjects: 41

Group type: COMPARATOR
Intervention: PSV alone (PSV group)
Number of subjects: 41

Group type: COMPARATOR
Intervention: PSV group
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: ATC group
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 17402650

Group type: EXPERIMENTAL
Intervention: Topical antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15253399

Group type: EXPERIMENTAL
Intervention: 100 mg elemental iron daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: 200 mg elemental iron weekly
Number of subjects: 100
Study: 11226079

Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (2430 +/- 310 mL administered until the morning of the first postoperative day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Gelatin (2830 +/- 350 mL administered until the morning of the first postoperative day)
Number of subjects: 42
Study: 9722272

Group type: EXPERIMENTAL
Intervention: Biodegradable barriers (Polyglactin 910)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Non-resorbable barriers (ePTFE)
Number of subjects: 23
Study: 7974672

Group type: EXPERIMENTAL
Intervention: Maloprim (pyrimethamine+dapsone)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 2655967

Group type: EXPERIMENTAL
Intervention: Electrophysiologic study
Number of subjects: 500

Group type: COMPARATOR
Intervention: Holter monitoring
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (mexiletine, pirmenol, procainamide, propafenone, quinidine, sotalol)
Number of subjects: 500
Study: 4609545

Group type: EXPERIMENTAL
Intervention: mepiprazole
Number of subjects: 19

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study: 29970009

Group type: EXPERIMENTAL
Intervention: CURB‐65 severity score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HEART score
Number of subjects: 0
Study: 26868469

Group type: EXPERIMENTAL
Intervention: 5% amlexanox (lexanox 5% oral paste)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 50
Study: 25796693

Group type: EXPERIMENTAL
Intervention: Longbishu Capsule combined with mesylate doxazosin
Number of subjects: 60

Group type: COMPARATOR
Intervention: mesylate doxazosin plus placebo
Number of subjects: 60
Study: 23078067

Group type: EXPERIMENTAL
Intervention: One-presentation/s 44-region protocol
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: All four test variants
Number of subjects: 63
Study: 20001867

Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with paclitaxel or docetaxel
Number of subjects: 0
Study: 17889983

Group type: EXPERIMENTAL
Intervention: Dinoprostone gel
Number of subjects: 320

Group type: COMPARATOR
Intervention: Dinoprostone insert
Number of subjects: 320
Study: 16177944

Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 0
Study: 12691345

Group type: EXPERIMENTAL
Intervention: TEAM program
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no TEAM program)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Evaluation questionnaire
Number of subjects: 29
Study: 10383538

Group type: EXPERIMENTAL
Intervention: Inhaled (INH) 20 mg sodium cromoglycate
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Inhaled + oral charcoal (INHC) 20 mg sodium cromoglycate
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oral (ORAL) 20 mg sodium cromoglycate
Number of subjects: 11

Group type: COMPARATOR
Intervention: Oral + oral charcoal (ORALC) 20 mg sodium cromoglycate
Number of subjects: 11
Study: 8983611

Group type: EXPERIMENTAL
Intervention: Bupivacaine (total of 20 ml, 0.25 per cent) injected into the subcutaneous periportal tissue and periportal parietal peritoneal injection of bupivacaine (total of 20 ml, 0.25 per cent)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard technique with bupivacaine (total of 20 ml, 0.5 per cent) injected into the subcutaneous periportal tissue
Number of subjects: 80
Study: 1840158

Group type: EXPERIMENTAL
Intervention: ciclopiroxolamine (cic) cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: ciclopiroxolamine (cic)
Number of subjects: 20
Study: 7055343

Group type: EXPERIMENTAL
Intervention: Fenoterol (Berotec) delivered as inhalation powder
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fenoterol from an aerosol inhaler
Number of subjects: 15
Study: 31126258

Group type: COMPARATOR
Intervention: Chemotherapy (CT) alone
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus trastuzumab (T)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus trastuzumab (T) plus pertuzumab (P)
Number of subjects: 215
Study: 30383086

Group type: EXPERIMENTAL
Intervention: PREPARE plus an easy-to-read advance directive
Number of subjects: 986

Group type: COMPARATOR
Intervention: Advance directive alone
Number of subjects: 986
Study: 28506281

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI), six sessions (60 minutes each), telephonically delivered
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 60
Study: 24038152

Group type: EXPERIMENTAL
Intervention: ONO-5334 300 mg QD
Number of subjects: 147

Group type: COMPARATOR
Intervention: Alendronate 70 mg QW
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: ONO-5334
Number of subjects: 147
Study: 23587455

Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib at a dose of 40 mg followed by 40 mg every 12 h for 48 h (Group P)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline as a control (Group C)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (Group P and Group C)
Number of subjects: 80
Study: 20459801

Group type: EXPERIMENTAL
Intervention: Low-dose continuous infusion of furosemide, titrated to urine output
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 18284632

Group type: EXPERIMENTAL
Intervention: Dietary recommendations
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Physical training classes
Number of subjects: 100

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 100
Study: 16629791

Group type: EXPERIMENTAL
Intervention: Salt chamber treatment (active group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study: 14636104

Group type: EXPERIMENTAL
Intervention: Effervescent creatine, ribose, and glutamine supplementation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 28
Study: 11185635

Group type: EXPERIMENTAL
Intervention: Telmisartan 120 mg administered between dialyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telmisartan 120 mg administered during dialysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy male subjects (control group)
Number of subjects: 0
Study: 8866807

Group type: EXPERIMENTAL
Intervention: qd SSKI (one daily dose)
Number of subjects: 57

Group type: COMPARATOR
Intervention: tid SSKI (three daily doses)
Number of subjects: 57
Study: 8499751

Group type: EXPERIMENTAL
Intervention: Pseudomonas hyperimmunoglobulin (Psomaglobin N) 250 mg/kg on days 3, 5, 7, 10, and 13
Number of subjects: 30

Group type: COMPARATOR
Intervention: No additional therapy (Control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups with inhalation injury
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bacteremic controls
Number of subjects: 30
Study: 3565818

Group type: EXPERIMENTAL
Intervention: enflurane/nitrous oxide/oxygen
Number of subjects: 780

Group type: COMPARATOR
Intervention: enflurane/air/oxygen
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: isoflurane/nitrous oxide/oxygen
Number of subjects: 780

Group type: COMPARATOR
Intervention: isoflurane/air/oxygen
Number of subjects: 780
Study: 31563889

Group type: EXPERIMENTAL
Intervention: First pass recanalization (FPR)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Balloon guide catheter use
Number of subjects: 429

Group type: COMPARATOR
Intervention: Multiple passes or rescue treatment
Number of subjects: 429
Study: 30264120

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy with intravenous ertapenem for 3 days followed by 7 days of oral levofloxacin and metronidazole
Number of subjects: 530

Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 530

Group type: COMPARATOR
Intervention: Antibiotic therapy
Number of subjects: 530
Study: 26561409

Group type: EXPERIMENTAL
Intervention: High eating frequency (8 eating occasions/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low eating frequency (3 eating occasions/d)
Number of subjects: 12
Study: 25011647

Group type: EXPERIMENTAL
Intervention: 10 grams of prebiotic (inulin/oligofructose) daily for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: 10 grams placebo (maltodextrin) daily for 12 weeks
Number of subjects: 30
Study: 24154738

Group type: EXPERIMENTAL
Intervention: Mericitabine plus peginterferon alfa-2a/ribavirin
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Double mutant L159F/L320F
Number of subjects: 405
Study: 22138360

Group type: EXPERIMENTAL
Intervention: Fermented sea tangle (FST) 1.5 g/day for 4 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 20124794

Group type: EXPERIMENTAL
Intervention: 20% MVIC
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 50% MVIC
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 100% MVIC
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 64.3% MVIC
Number of subjects: 56
Study: 17335309

Group type: EXPERIMENTAL
Intervention: Medication Events Monitoring System (MEMS)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 253
Study: 15709078

Group type: EXPERIMENTAL
Intervention: Opportunistic screening
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Postal screening
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 600
Study: 11889013

Group type: EXPERIMENTAL
Intervention: Systolic heart failure (SHF)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Diastolic heart failure (DHF)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Isolated diastolic dysfunction (DD)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Presence of systolic dysfunction
Number of subjects: 339
Study: 10448449

Group type: EXPERIMENTAL
Intervention: Mianserin (15 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9038524

Group type: EXPERIMENTAL
Intervention: Mild stimulant laxative (Dulcolax)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Osmotic laxative (Citramag)
Number of subjects: 144

Group type: COMPARATOR
Intervention: No preparation
Number of subjects: 144
Study: 1380006

Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 546

Group type: COMPARATOR
Intervention: Conventional embryo transfers
Number of subjects: 546
Study: 6499715

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study: 31829232

Group type: EXPERIMENTAL
Intervention: PRIDE intervention offered in addition to usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study: 29396845

Group type: EXPERIMENTAL
Intervention: Multiple-choice trial with genotypes HS-20, OE, VA
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Multiple-choice test with genotypes LG, VE, J, MG, MOP, HS-20, VA, MT
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: No-choice oviposition test with genotypes VE, P1C, CCB, RI-919, H, J
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Genotypes VE and J
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Genotypes HS-20, OE, VA, VE, J
Number of subjects: 32
Study: 27103607

Group type: COMPARATOR
Intervention: Biologic therapies targeting immunoglobulin E (IgE) and interleukin (IL)-5 pathways in CRSwNP patients.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biologic therapies targeting the IL-4/IL-13 pathway and other type 2 inflammatory pathways in CRSwNP patients.
Number of subjects: 0
Study: 24292155

Group type: EXPERIMENTAL
Intervention: Q-switched Nd:YAG laser plus Er:YAG micropeel (combined therapy)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Q-switched Nd:YAG laser (QSNY) alone
Number of subjects: 15
Study: 21442171

Group type: EXPERIMENTAL
Intervention: 12-week supervised training programme consisting of 3 weekly sessions of aerobic, strengthening and flexibility exercises
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 28
Study: 20047363

Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide exposure (4 ppm)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Filtered air (control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bradykinin (100-1000 pmol/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acetylcholine (5-20 microg/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (2-8 microg/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Verapamil (10-100 microg/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lung function assessment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exhaled nitric oxide measurement
Number of subjects: 10
Study: 17410949

Group type: EXPERIMENTAL
Intervention: Stannous fluoride + sodium hexametaphosphate dentifrice (Crest Pro‐Health)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Positive control toothpaste (Colgate Total Plus Whitening)
Number of subjects: 116
Study: 15845756

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG, 100 mg-400 mg/day, mean modal dose 240 mg)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Lithium (Li, 0.8 mEq/L-1.1 mEq/L, mean modal dose 750 mg)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 98
Study: 11983755

Group type: EXPERIMENTAL
Intervention: Outreach worker intervention
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Direct mail intervention
Number of subjects: 482

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 482
Study: 9862288

Group type: EXPERIMENTAL
Intervention: Moderate intensity strength exercise (elastic band resistance training, at least 3 times a week for 6 months)
Number of subjects: 132

Group type: COMPARATOR
Intervention: No-exercise control
Number of subjects: 132
Study: 7622805

Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 279

Group type: COMPARATOR
Intervention: Norepinephrine (NE) reuptake inhibitors
Number of subjects: 279

Group type: COMPARATOR
Intervention: Mixed NE/serotonin reuptake inhibitors
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 1320846

Group type: EXPERIMENTAL
Intervention: 254-S plus VDS
Number of subjects: 136

Group type: COMPARATOR
Intervention: CDDP plus VDS
Number of subjects: 136
Study: 6418691

Group type: EXPERIMENTAL
Intervention: Amino acid mixture plus carbohydrates (Gp I)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Amino acid mixture plus lipids and carbohydrates (Gp II)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Solid-food general hospital diet (Gp III - control)
Number of subjects: 14
Study: 31606362

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 79
Study: 29672552

Group type: EXPERIMENTAL
Intervention: MenACWY vaccination
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MenC vaccination
Number of subjects: 100

Group type: COMPARATOR
Intervention: MenC and MenACWY vaccinations
Number of subjects: 100
Study: 26091997

Group type: EXPERIMENTAL
Intervention: Goal-directed hands-on training session (Sim group)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Unstructured hands-on session (control group)
Number of subjects: 289
Study: 24315521

Group type: EXPERIMENTAL
Intervention: Active elastic compression stockings (ECS) used for 2 years
Number of subjects: 806

Group type: COMPARATOR
Intervention: Placebo elastic compression stockings (ECS) used for 2 years
Number of subjects: 806
Study: 22257341

Group type: EXPERIMENTAL
Intervention: Dentaport ZX
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Raypex 5
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ProPex II
Number of subjects: 30